img

Global Idiopathic Gastroparesis Drugs Market Research Report 2024


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Idiopathic Gastroparesis Drugs Market Research Report 2024

Medications are used to try to help reduce symptoms of gastroparesis. The drug categories commonly used are prokinetic (promotility) agents and antiemetic agents.
According to Mr Accuracy reports’s new survey, global Idiopathic Gastroparesis Drugs market is projected to reach US$ 5125.5 million in 2034, increasing from US$ 3565.2 million in 2024, with the CAGR of 5.4% during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Idiopathic Gastroparesis Drugs market research.
Key companies engaged in the Idiopathic Gastroparesis Drugs industry include Sumitomo, Cadila Pharmaceuticals, Sanofi, Teva, Johnson & Johnson, Pfizer, Kyowa Kirin Pharmaceuticals, Hanmi Pharm and Ani Pharmaceuticals, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2024.
When refers to consumption region, % value of Idiopathic Gastroparesis Drugs were sold to North America, Europe and Asia Pacific in 2024. Moreover, China, plays a key role in the whole Idiopathic Gastroparesis Drugs market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Idiopathic Gastroparesis Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


Sumitomo
Cadila Pharmaceuticals
Sanofi
Teva
Johnson & Johnson
Pfizer
Kyowa Kirin Pharmaceuticals
Hanmi Pharm
Ani Pharmaceuticals
Segment by Type
Prokinetic Agents
Antiemetic Agents
Others

Segment by Application


Hospital Pharmacies
Private Clinics
Drug Stores
E-Commerce
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Idiopathic Gastroparesis Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Idiopathic Gastroparesis Drugs Market Size Growth Rate by Type: 2018 VS 2024 VS 2034
1.2.2 Prokinetic Agents
1.2.3 Antiemetic Agents
1.2.4 Others
1.3 Market by Application
1.3.1 Global Idiopathic Gastroparesis Drugs Market Growth by Application: 2018 VS 2024 VS 2034
1.3.2 Hospital Pharmacies
1.3.3 Private Clinics
1.3.4 Drug Stores
1.3.5 E-Commerce
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Idiopathic Gastroparesis Drugs Market Perspective (2018-2034)
2.2 Idiopathic Gastroparesis Drugs Growth Trends by Region
2.2.1 Global Idiopathic Gastroparesis Drugs Market Size by Region: 2018 VS 2024 VS 2034
2.2.2 Idiopathic Gastroparesis Drugs Historic Market Size by Region (2018-2023)
2.2.3 Idiopathic Gastroparesis Drugs Forecasted Market Size by Region (2024-2034)
2.3 Idiopathic Gastroparesis Drugs Market Dynamics
2.3.1 Idiopathic Gastroparesis Drugs Industry Trends
2.3.2 Idiopathic Gastroparesis Drugs Market Drivers
2.3.3 Idiopathic Gastroparesis Drugs Market Challenges
2.3.4 Idiopathic Gastroparesis Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Idiopathic Gastroparesis Drugs Players by Revenue
3.1.1 Global Top Idiopathic Gastroparesis Drugs Players by Revenue (2018-2023)
3.1.2 Global Idiopathic Gastroparesis Drugs Revenue Market Share by Players (2018-2023)
3.2 Global Idiopathic Gastroparesis Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Idiopathic Gastroparesis Drugs Revenue
3.4 Global Idiopathic Gastroparesis Drugs Market Concentration Ratio
3.4.1 Global Idiopathic Gastroparesis Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Idiopathic Gastroparesis Drugs Revenue in 2024
3.5 Idiopathic Gastroparesis Drugs Key Players Head office and Area Served
3.6 Key Players Idiopathic Gastroparesis Drugs Product Solution and Service
3.7 Date of Enter into Idiopathic Gastroparesis Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Idiopathic Gastroparesis Drugs Breakdown Data by Type
4.1 Global Idiopathic Gastroparesis Drugs Historic Market Size by Type (2018-2023)
4.2 Global Idiopathic Gastroparesis Drugs Forecasted Market Size by Type (2024-2034)
5 Idiopathic Gastroparesis Drugs Breakdown Data by Application
5.1 Global Idiopathic Gastroparesis Drugs Historic Market Size by Application (2018-2023)
5.2 Global Idiopathic Gastroparesis Drugs Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America Idiopathic Gastroparesis Drugs Market Size (2018-2034)
6.2 North America Idiopathic Gastroparesis Drugs Market Growth Rate by Country: 2018 VS 2024 VS 2034
6.3 North America Idiopathic Gastroparesis Drugs Market Size by Country (2018-2023)
6.4 North America Idiopathic Gastroparesis Drugs Market Size by Country (2024-2034)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Idiopathic Gastroparesis Drugs Market Size (2018-2034)
7.2 Europe Idiopathic Gastroparesis Drugs Market Growth Rate by Country: 2018 VS 2024 VS 2034
7.3 Europe Idiopathic Gastroparesis Drugs Market Size by Country (2018-2023)
7.4 Europe Idiopathic Gastroparesis Drugs Market Size by Country (2024-2034)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Idiopathic Gastroparesis Drugs Market Size (2018-2034)
8.2 Asia-Pacific Idiopathic Gastroparesis Drugs Market Growth Rate by Region: 2018 VS 2024 VS 2034
8.3 Asia-Pacific Idiopathic Gastroparesis Drugs Market Size by Region (2018-2023)
8.4 Asia-Pacific Idiopathic Gastroparesis Drugs Market Size by Region (2024-2034)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Idiopathic Gastroparesis Drugs Market Size (2018-2034)
9.2 Latin America Idiopathic Gastroparesis Drugs Market Growth Rate by Country: 2018 VS 2024 VS 2034
9.3 Latin America Idiopathic Gastroparesis Drugs Market Size by Country (2018-2023)
9.4 Latin America Idiopathic Gastroparesis Drugs Market Size by Country (2024-2034)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Idiopathic Gastroparesis Drugs Market Size (2018-2034)
10.2 Middle East & Africa Idiopathic Gastroparesis Drugs Market Growth Rate by Country: 2018 VS 2024 VS 2034
10.3 Middle East & Africa Idiopathic Gastroparesis Drugs Market Size by Country (2018-2023)
10.4 Middle East & Africa Idiopathic Gastroparesis Drugs Market Size by Country (2024-2034)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sumitomo
11.1.1 Sumitomo Company Detail
11.1.2 Sumitomo Business Overview
11.1.3 Sumitomo Idiopathic Gastroparesis Drugs Introduction
11.1.4 Sumitomo Revenue in Idiopathic Gastroparesis Drugs Business (2018-2023)
11.1.5 Sumitomo Recent Development
11.2 Cadila Pharmaceuticals
11.2.1 Cadila Pharmaceuticals Company Detail
11.2.2 Cadila Pharmaceuticals Business Overview
11.2.3 Cadila Pharmaceuticals Idiopathic Gastroparesis Drugs Introduction
11.2.4 Cadila Pharmaceuticals Revenue in Idiopathic Gastroparesis Drugs Business (2018-2023)
11.2.5 Cadila Pharmaceuticals Recent Development
11.3 Sanofi
11.3.1 Sanofi Company Detail
11.3.2 Sanofi Business Overview
11.3.3 Sanofi Idiopathic Gastroparesis Drugs Introduction
11.3.4 Sanofi Revenue in Idiopathic Gastroparesis Drugs Business (2018-2023)
11.3.5 Sanofi Recent Development
11.4 Teva
11.4.1 Teva Company Detail
11.4.2 Teva Business Overview
11.4.3 Teva Idiopathic Gastroparesis Drugs Introduction
11.4.4 Teva Revenue in Idiopathic Gastroparesis Drugs Business (2018-2023)
11.4.5 Teva Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Detail
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Idiopathic Gastroparesis Drugs Introduction
11.5.4 Johnson & Johnson Revenue in Idiopathic Gastroparesis Drugs Business (2018-2023)
11.5.5 Johnson & Johnson Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Detail
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Idiopathic Gastroparesis Drugs Introduction
11.6.4 Pfizer Revenue in Idiopathic Gastroparesis Drugs Business (2018-2023)
11.6.5 Pfizer Recent Development
11.7 Kyowa Kirin Pharmaceuticals
11.7.1 Kyowa Kirin Pharmaceuticals Company Detail
11.7.2 Kyowa Kirin Pharmaceuticals Business Overview
11.7.3 Kyowa Kirin Pharmaceuticals Idiopathic Gastroparesis Drugs Introduction
11.7.4 Kyowa Kirin Pharmaceuticals Revenue in Idiopathic Gastroparesis Drugs Business (2018-2023)
11.7.5 Kyowa Kirin Pharmaceuticals Recent Development
11.8 Hanmi Pharm
11.8.1 Hanmi Pharm Company Detail
11.8.2 Hanmi Pharm Business Overview
11.8.3 Hanmi Pharm Idiopathic Gastroparesis Drugs Introduction
11.8.4 Hanmi Pharm Revenue in Idiopathic Gastroparesis Drugs Business (2018-2023)
11.8.5 Hanmi Pharm Recent Development
11.9 Ani Pharmaceuticals
11.9.1 Ani Pharmaceuticals Company Detail
11.9.2 Ani Pharmaceuticals Business Overview
11.9.3 Ani Pharmaceuticals Idiopathic Gastroparesis Drugs Introduction
11.9.4 Ani Pharmaceuticals Revenue in Idiopathic Gastroparesis Drugs Business (2018-2023)
11.9.5 Ani Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Idiopathic Gastroparesis Drugs Market Size Growth Rate by Type (US$ Million): 2018 VS 2024 VS 2034
Table 2. Key Players of Prokinetic Agents
Table 3. Key Players of Antiemetic Agents
Table 4. Key Players of Others
Table 5. Global Idiopathic Gastroparesis Drugs Market Size Growth by Application (US$ Million): 2018 VS 2024 VS 2034
Table 6. Global Idiopathic Gastroparesis Drugs Market Size by Region (US$ Million): 2018 VS 2024 VS 2034
Table 7. Global Idiopathic Gastroparesis Drugs Market Size by Region (2018-2023) & (US$ Million)
Table 8. Global Idiopathic Gastroparesis Drugs Market Share by Region (2018-2023)
Table 9. Global Idiopathic Gastroparesis Drugs Forecasted Market Size by Region (2024-2034) & (US$ Million)
Table 10. Global Idiopathic Gastroparesis Drugs Market Share by Region (2024-2034)
Table 11. Idiopathic Gastroparesis Drugs Market Trends
Table 12. Idiopathic Gastroparesis Drugs Market Drivers
Table 13. Idiopathic Gastroparesis Drugs Market Challenges
Table 14. Idiopathic Gastroparesis Drugs Market Restraints
Table 15. Global Idiopathic Gastroparesis Drugs Revenue by Players (2018-2023) & (US$ Million)
Table 16. Global Idiopathic Gastroparesis Drugs Market Share by Players (2018-2023)
Table 17. Global Top Idiopathic Gastroparesis Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Idiopathic Gastroparesis Drugs as of 2024)
Table 18. Ranking of Global Top Idiopathic Gastroparesis Drugs Companies by Revenue (US$ Million) in 2024
Table 19. Global 5 Largest Players Market Share by Idiopathic Gastroparesis Drugs Revenue (CR5 and HHI) & (2018-2023)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Idiopathic Gastroparesis Drugs Product Solution and Service
Table 22. Date of Enter into Idiopathic Gastroparesis Drugs Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Idiopathic Gastroparesis Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 25. Global Idiopathic Gastroparesis Drugs Revenue Market Share by Type (2018-2023)
Table 26. Global Idiopathic Gastroparesis Drugs Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 27. Global Idiopathic Gastroparesis Drugs Revenue Market Share by Type (2024-2034)
Table 28. Global Idiopathic Gastroparesis Drugs Market Size by Application (2018-2023) & (US$ Million)
Table 29. Global Idiopathic Gastroparesis Drugs Revenue Market Share by Application (2018-2023)
Table 30. Global Idiopathic Gastroparesis Drugs Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 31. Global Idiopathic Gastroparesis Drugs Revenue Market Share by Application (2024-2034)
Table 32. North America Idiopathic Gastroparesis Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2024 VS 2034
Table 33. North America Idiopathic Gastroparesis Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 34. North America Idiopathic Gastroparesis Drugs Market Size by Country (2024-2034) & (US$ Million)
Table 35. Europe Idiopathic Gastroparesis Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2024 VS 2034
Table 36. Europe Idiopathic Gastroparesis Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 37. Europe Idiopathic Gastroparesis Drugs Market Size by Country (2024-2034) & (US$ Million)
Table 38. Asia-Pacific Idiopathic Gastroparesis Drugs Market Size Growth Rate by Region (US$ Million): 2018 VS 2024 VS 2034
Table 39. Asia-Pacific Idiopathic Gastroparesis Drugs Market Size by Region (2018-2023) & (US$ Million)
Table 40. Asia-Pacific Idiopathic Gastroparesis Drugs Market Size by Region (2024-2034) & (US$ Million)
Table 41. Latin America Idiopathic Gastroparesis Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2024 VS 2034
Table 42. Latin America Idiopathic Gastroparesis Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 43. Latin America Idiopathic Gastroparesis Drugs Market Size by Country (2024-2034) & (US$ Million)
Table 44. Middle East & Africa Idiopathic Gastroparesis Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2024 VS 2034
Table 45. Middle East & Africa Idiopathic Gastroparesis Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 46. Middle East & Africa Idiopathic Gastroparesis Drugs Market Size by Country (2024-2034) & (US$ Million)
Table 47. Sumitomo Company Detail
Table 48. Sumitomo Business Overview
Table 49. Sumitomo Idiopathic Gastroparesis Drugs Product
Table 50. Sumitomo Revenue in Idiopathic Gastroparesis Drugs Business (2018-2023) & (US$ Million)
Table 51. Sumitomo Recent Development
Table 52. Cadila Pharmaceuticals Company Detail
Table 53. Cadila Pharmaceuticals Business Overview
Table 54. Cadila Pharmaceuticals Idiopathic Gastroparesis Drugs Product
Table 55. Cadila Pharmaceuticals Revenue in Idiopathic Gastroparesis Drugs Business (2018-2023) & (US$ Million)
Table 56. Cadila Pharmaceuticals Recent Development
Table 57. Sanofi Company Detail
Table 58. Sanofi Business Overview
Table 59. Sanofi Idiopathic Gastroparesis Drugs Product
Table 60. Sanofi Revenue in Idiopathic Gastroparesis Drugs Business (2018-2023) & (US$ Million)
Table 61. Sanofi Recent Development
Table 62. Teva Company Detail
Table 63. Teva Business Overview
Table 64. Teva Idiopathic Gastroparesis Drugs Product
Table 65. Teva Revenue in Idiopathic Gastroparesis Drugs Business (2018-2023) & (US$ Million)
Table 66. Teva Recent Development
Table 67. Johnson & Johnson Company Detail
Table 68. Johnson & Johnson Business Overview
Table 69. Johnson & Johnson Idiopathic Gastroparesis Drugs Product
Table 70. Johnson & Johnson Revenue in Idiopathic Gastroparesis Drugs Business (2018-2023) & (US$ Million)
Table 71. Johnson & Johnson Recent Development
Table 72. Pfizer Company Detail
Table 73. Pfizer Business Overview
Table 74. Pfizer Idiopathic Gastroparesis Drugs Product
Table 75. Pfizer Revenue in Idiopathic Gastroparesis Drugs Business (2018-2023) & (US$ Million)
Table 76. Pfizer Recent Development
Table 77. Kyowa Kirin Pharmaceuticals Company Detail
Table 78. Kyowa Kirin Pharmaceuticals Business Overview
Table 79. Kyowa Kirin Pharmaceuticals Idiopathic Gastroparesis Drugs Product
Table 80. Kyowa Kirin Pharmaceuticals Revenue in Idiopathic Gastroparesis Drugs Business (2018-2023) & (US$ Million)
Table 81. Kyowa Kirin Pharmaceuticals Recent Development
Table 82. Hanmi Pharm Company Detail
Table 83. Hanmi Pharm Business Overview
Table 84. Hanmi Pharm Idiopathic Gastroparesis Drugs Product
Table 85. Hanmi Pharm Revenue in Idiopathic Gastroparesis Drugs Business (2018-2023) & (US$ Million)
Table 86. Hanmi Pharm Recent Development
Table 87. Ani Pharmaceuticals Company Detail
Table 88. Ani Pharmaceuticals Business Overview
Table 89. Ani Pharmaceuticals Idiopathic Gastroparesis Drugs Product
Table 90. Ani Pharmaceuticals Revenue in Idiopathic Gastroparesis Drugs Business (2018-2023) & (US$ Million)
Table 91. Ani Pharmaceuticals Recent Development
Table 92. Research Programs/Design for This Report
Table 93. Key Data Information from Secondary Sources
Table 94. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Idiopathic Gastroparesis Drugs Market Size Comparison by Type (2024-2034) & (US$ Million)
Figure 2. Global Idiopathic Gastroparesis Drugs Market Share by Type: 2024 VS 2034
Figure 3. Prokinetic Agents Features
Figure 4. Antiemetic Agents Features
Figure 5. Others Features
Figure 6. Global Idiopathic Gastroparesis Drugs Market Size Comparison by Application (2024-2034) & (US$ Million)
Figure 7. Global Idiopathic Gastroparesis Drugs Market Share by Application: 2024 VS 2034
Figure 8. Hospital Pharmacies Case Studies
Figure 9. Private Clinics Case Studies
Figure 10. Drug Stores Case Studies
Figure 11. E-Commerce Case Studies
Figure 12. Idiopathic Gastroparesis Drugs Report Years Considered
Figure 13. Global Idiopathic Gastroparesis Drugs Market Size (US$ Million), Year-over-Year: 2018-2034
Figure 14. Global Idiopathic Gastroparesis Drugs Market Size, (US$ Million), 2018 VS 2024 VS 2034
Figure 15. Global Idiopathic Gastroparesis Drugs Market Share by Region: 2024 VS 2034
Figure 16. Global Idiopathic Gastroparesis Drugs Market Share by Players in 2024
Figure 17. Global Top Idiopathic Gastroparesis Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Idiopathic Gastroparesis Drugs as of 2024)
Figure 18. The Top 10 and 5 Players Market Share by Idiopathic Gastroparesis Drugs Revenue in 2024
Figure 19. North America Idiopathic Gastroparesis Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 20. North America Idiopathic Gastroparesis Drugs Market Share by Country (2018-2034)
Figure 21. United States Idiopathic Gastroparesis Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 22. Canada Idiopathic Gastroparesis Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 23. Europe Idiopathic Gastroparesis Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 24. Europe Idiopathic Gastroparesis Drugs Market Share by Country (2018-2034)
Figure 25. Germany Idiopathic Gastroparesis Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 26. France Idiopathic Gastroparesis Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 27. U.K. Idiopathic Gastroparesis Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 28. Italy Idiopathic Gastroparesis Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 29. Russia Idiopathic Gastroparesis Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 30. Nordic Countries Idiopathic Gastroparesis Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 31. Asia-Pacific Idiopathic Gastroparesis Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 32. Asia-Pacific Idiopathic Gastroparesis Drugs Market Share by Region (2018-2034)
Figure 33. China Idiopathic Gastroparesis Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 34. Japan Idiopathic Gastroparesis Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 35. South Korea Idiopathic Gastroparesis Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 36. Southeast Asia Idiopathic Gastroparesis Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 37. India Idiopathic Gastroparesis Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 38. Australia Idiopathic Gastroparesis Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 39. Latin America Idiopathic Gastroparesis Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 40. Latin America Idiopathic Gastroparesis Drugs Market Share by Country (2018-2034)
Figure 41. Mexico Idiopathic Gastroparesis Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 42. Brazil Idiopathic Gastroparesis Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 43. Middle East & Africa Idiopathic Gastroparesis Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 44. Middle East & Africa Idiopathic Gastroparesis Drugs Market Share by Country (2018-2034)
Figure 45. Turkey Idiopathic Gastroparesis Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 46. Saudi Arabia Idiopathic Gastroparesis Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 47. Sumitomo Revenue Growth Rate in Idiopathic Gastroparesis Drugs Business (2018-2023)
Figure 48. Cadila Pharmaceuticals Revenue Growth Rate in Idiopathic Gastroparesis Drugs Business (2018-2023)
Figure 49. Sanofi Revenue Growth Rate in Idiopathic Gastroparesis Drugs Business (2018-2023)
Figure 50. Teva Revenue Growth Rate in Idiopathic Gastroparesis Drugs Business (2018-2023)
Figure 51. Johnson & Johnson Revenue Growth Rate in Idiopathic Gastroparesis Drugs Business (2018-2023)
Figure 52. Pfizer Revenue Growth Rate in Idiopathic Gastroparesis Drugs Business (2018-2023)
Figure 53. Kyowa Kirin Pharmaceuticals Revenue Growth Rate in Idiopathic Gastroparesis Drugs Business (2018-2023)
Figure 54. Hanmi Pharm Revenue Growth Rate in Idiopathic Gastroparesis Drugs Business (2018-2023)
Figure 55. Ani Pharmaceuticals Revenue Growth Rate in Idiopathic Gastroparesis Drugs Business (2018-2023)
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed